Recent News

  • 11:06 AM Jun 9th
    NEJM: “How can we fairly allocate medical resources during a pandemic?” - application of 4 values into 6 specific recommendations for ethical framework. The goal to develop guidelines that  are fair, transparent, and prevent the “acute and life-long emotional toll” on clinicians of improvising. 
  • 03:06 PM Jun 8th
    Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine
  • 03:06 PM Jun 8th
    The Lancet - retraction of hydroxychloroquine or chloroquine with or without macrolide in COVID-19 paper due to Surgisphere non release of data for independent analysis.
  • 02:06 PM Jun 8th
    NEJM ACTT-1 adaptive trial program preliminary results of 10-days remdesivir vs placebo for hospitalised COVI-19 patients, shorter time to recovery (11 vs 15 days), RR 1.32; 95% CI 1.12 to 1.55; P<0.001. No benefit observed if MV/ ECMO at enrolment, although wide CI. Trial ongoing  DSM unblind and release as possible immediate benefit. Authors recommend use of remdesivir for hospitalised patients who require supplemental oxygen.
  • 02:06 PM Jun 8th
    NEJM: Open label RCT of remdesivir for 5-days vs 10-days in hospitalised COVID-19 with hypoxia reports 65% (5-day) vs 54% (10-day) had clinical improvement by D14, after adjustment for baseline difference in clinical status, similar distribution. These results cannot be extrapolated to critically ill patients receiving mechanical ventilation, as the proportion was low, and patients who progress to MV may benefit from a longer course. 

Social Media